MABPRO, a.s. is focused on the development and commercialization of CA IX-targeted therapy and diagnostics.
We believe that we will introduce our early-stage pharmaceuticals in the foreseeable future.
Results of all clinical studies strongly recommend to evaluate CA IX as an endogenous marker of tumor hypoxia and a biological factor of therapy resistance.
As response to these unmet needs of clinical practice we are developing the diagnostic products for CA IX detection. We will introduce them in the foreseeable future.
Dúbravská cesta 2
841 04 Bratislava
ID. No.: 36 831 930
VAT Reg. No.: SK2022456678
Registered in Commercial register of Bratislava I District Court
Section: Sa, file no.: 6337/B